ACE-031 and YK-11 Interaction

Monitor
Researched 90% confidence

ACE-031 and YK-11 have an interaction requiring monitoring for interaction with 90% confidence. Both target the myostatin pathway. YK-11 acts as a myostatin inhibitor through a different mechanism. Combined use could produce excessive pathway suppression with unpredictable effects. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Half-life: 12-15 days Typical dose: 0.5-3 mg/kg IV every 2 weeks (clinical research doses only) growth hormone, anabolic
actriibmyostatintgf beta androgenicanticoagulantblood pressure raisinghpta suppressive
View full profile

YK-11

Myostatin Inhibitor & SARM Hybrid | Experimental

YK-11 exerts its effects through two distinct but complementary pathways. First, it acts as a partial agonist of the androgen receptor (AR).

Half-life: ~6-10 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptormyostatintgf beta androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
moderate
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (ACE-031, YK-11). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds raise blood pressure (ACE-031, YK-11). Monitor BP daily and consider cardiovascular support.
2x 2 HPTA-suppressive compounds (ACE-031, YK-11). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (ACE-031, YK-11). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (ACE-031, YK-11). Monitor accordingly.

Frequently Asked Questions

Can I take ACE-031 with YK-11?

Yes, but with caution. Both target the myostatin pathway. YK-11 acts as a myostatin inhibitor through a different mechanism. Combined use could produce excessive pathway suppression with unpredictable effects. Regular monitoring is advised.

Is ACE-031 and YK-11 safe together?

Based on documented research, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between ACE-031 and YK-11?

Both target the myostatin pathway. YK-11 acts as a myostatin inhibitor through a different mechanism. Combined use could produce excessive pathway suppression with unpredictable effects. This assessment has 90% confidence and is based on documented research data.

How should I time ACE-031 and YK-11?

ACE-031 has a half-life of 12-15 days and YK-11 has a half-life of ~6-10 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: ACE-031 vs YK-11

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.